Merck & Co Inc (NYSE:MRK)
| 88.39 Delayed Data As of Oct 05 |  0.00 / 0.00%Today’s Change | 71.50 Today|||52-Week Range 95.72 | +15.33% Year-to-Date |
Latest MRK News | Press Releases
| Is Exelixis' (EXEL) Growth Story Likely to Continue? Oct 05 / Zacks.com - Paid Partner Content | What This News Means for Merck Oct 01 / MotleyFool.com - Paid Partner Content |
| Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy Oct 05 / Zacks.com - Paid Partner Content | The Best Value Stock to Buy for the Long Term Sep 29 / StockNews.com - Paid Partner Content |
| Merck (MRK) Gains But Lags Market: What You Should Know Oct 03 / Zacks.com - Paid Partner Content | Merck's (MRK) Keytruda Gets Four New Approvals in Japan Sep 28 / Zacks.com - Paid Partner Content |
| Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure? Oct 03 / Zacks.com - Paid Partner Content | Bear Market: 2 Safe Stocks to Buy Right Now Sep 28 / MotleyFool.com - Paid Partner Content |
| 2 Stocks to Add to Your Must-Buy List in Q4 Oct 03 / StockNews.com - Paid Partner Content | Should Invesco Dow Jones Industrial Average Dividend ETF (DJD) Be on Your Investing Radar? Sep 28 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 88.39 |
| Today’s open | 88.60 |
| Day’s range | 88.03 - 88.77 |
| Volume | 6,065,661 |
| Average volume (3 months) | 9,554,710 |
| Market cap | $218.2B |
Data as of 4:00pm ET, 10/05/2022
Growth & Valuation
| Earnings growth (last year) | +84.65% |
| Earnings growth (this year) | +22.76% |
| Earnings growth (next 5 years) | +11.30% |
| Revenue growth (last year) | +1.86% |
| P/E ratio | 13.5 |
| Price/Sales | 3.98 |
| Price/Book | 5.70 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | -0.35 | -0.79% |
| ABBVAbbVie | +1.23 | +0.87% |
| NVONovo Nordisk | +0.60 | +0.57% |
| AZNAstraZeneca | -0.34 | -0.60% |
Data as of 4:00pm ET, 10/05/2022
Financials
| Next reporting date | October 27, 2022 |
| EPS forecast (this quarter) | $1.75 |
| Annual revenue (last year) | $48.9B |
| Annual profit (last year) | $13.0B |
| Net profit margin | 25.24% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Kenilworth, New Jersey |
Forecasts
